Zhejiang Medicine600216.SHValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 19, 2026, Zhejiang Medicine (600216.SH) trades at a P/E of 14.50x, P/B of 1.00x, P/S of 1.33x, and a dividend yield of 2.30%.
Longitudinal percentile comparison: P/E sits at the 18th percentile over the trailing 10Y window (vs. 32nd percentile over 3Y); P/B sits at the 4th percentile over the trailing 10Y window (vs. 13th percentile over 3Y); P/S sits at the 12th percentile over the trailing 10Y window (vs. 26th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 8th percentile within its industry and the 13th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 4.02%, ranking at the 94th percentile over the trailing 20Y window.
The P/E and P/B long-window percentiles differ by only 13.7 points, pointing to a consistent valuation read across both metrics. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Breaking down the total shareholder yield: 2.30% comes from cash dividends, with an implied ~1.72% from buybacks — a fairly balanced mix of both channels. Zhejiang Medicine operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHA: 600216 · SSE: 600216 · 600216
Want the full picture on whether Zhejiang Medicine (600216.SH) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 14.50 | ||||||
| P/B (MRQ) | 1.00 | ||||||
| P/S (TTM) | 1.33 | ||||||
| Dividend Yield | 2.30% | ||||||
| Buyback + Div Yield | 4.02% |